Volver
Flu can be similar to a cold; however, it tends to start suddenly with high fever, sore throat, weakness, malaise, muscle pain (myalgia), stomach ache, joint pain (arthralgia), headache (cephalea) and cough that is generally dry and without mucus. It can also cause nausea, vomiting, and diarrhea, more often in children.
In human beings, it can affect the airways, that is to say, the nose, throat, bronchi, and, less frequently, the lungs. However, it can also affect the heart, brain, or muscles. Flu usually spontaneously heals in a few days, but in some cases, it may worsen due to complications that may turn out to be fatal, especially in little children, pregnant women, senior adults, or people with an impaired immune condition.
Flu globally spreads in seasonal patterns, whether as epidemics or pandemics that cause high morbidity and mortality. Annually, it occurs in autumn and winter in temperate zones. It spreads from infected individuals through spray drops charged with the virus that comes from nasal, bronchial secretion, or saliva that contains any of them when coughing or sneezing or just by talking. It is generally required a short distance (less than one meter) from the sick person to get infected.
In developed countries, yearly vaccination campaigns against flu are conducted for people with a higher risk to get the disease, or that are more vulnerable to its complications, as well as strict controls on poultry. The regular human vaccine is the trivalent vaccine, which contains purified and inactive proteins of the three strains that are considered will be more common in the next epidemic: two strains of influenza subtype A, and one strain of subtype B.6.
A vaccine engineered against seasonal and pandemic influenza of a certain year may not be efficient for later campaigns due to the frequent and fast mutations of the virus (changes in its antigens) and the change of the different dominant strains.
Fluxvir
Vacuna contra la influenza estacional y pandémica adyuvantada.
Dosing
See more
Fluxvir Fluxvir is a vaccine against seasonal and pandemic influenza, with MF59.1 adjuvant.
Higher immunogenicity and effectiveness in senior adults (>65 years old) compared to vaccines with no adjuvants.
Higher immunogenicity and effectiveness in senior adults (>65 years old) compared to vaccines with no adjuvants.
Higer immune response.
Cross protection against hetero variable strains.
Well tolerated.
Reduction of an about 25% in hospitalization risk.
Pre-filled single-dose syringe containing 0.5 ml.
Fluxvir - Dosing
4Flu
Vacuna contra la influenza estacional y pandémica cuadrivalente.
Dosing
See more
4Flu is a quadrivalent inactivated (split-virus) vaccine, indicated for the active immunization against the influenza A virus and influenza B virus contained in the vaccine.
Its active components are hemagglutinin antigen (HA) and neuraminidase antigen (NA)
It proved to be immunologically superior for B strain not included in theTIV.
It protects against the same viruses the trivalent vaccine does, but adding the protection against one more B virus strain.
It shows an adequate safety and tolerability profile.
WHO prequalified and approved by FDA (USA) and ANMAT (ARGENTINE NATIONAL ADMINISTRATION OF DRUGS, FOOD AND MEDICAL TECHNOLOGY).
Package with 1 and 10 pre-filled single-dose syringes of 0.25 ml and 0.5 ml.
4Flu - Dosing
Viraflu
Vacuna contra la influenza estacional y pandémica trivalente.
Dosing
See more
Viraflu® is an inactivated third-generation vaccine against seasonal and pandemic influenza, with surface antigens (of subunits), highly purified.
The active ingredients are highly purified HA antigen (hemagglutinin) and NA antigen (neuraminidase) that derive from the influenza strains the Pan American Health Organization (PAHO) yearly recommends to include in vaccines. These strains spread in embryonated chicken eggs and are later inactivated with formaldehyde.
Viraflu for Adults
Pre-filled single-dose syringe containing 0.5 ml.
Viraflu pediatric
Pre-filled single-dose syringe containing 0.25 ml.
Viraflu - Dosing
